L2167

L-165,041

≥98% (HPLC), powder

• Synonym(e): 4-[3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy­acetic acid
• Empirische Formel (Hill-System): C₂₂H₂₆O₇
• CAS-Nummer: 79558-09-1
• Molekulargewicht: 402.44
• MDL-Nummer: MFCD04974501
• UNSPSC-Code: 12352200
• PubChem Substanz-ID: 24278477
• NACRES: NA.77

Eigenschaften

• Assay: ≥98% (HPLC)
• Form: powder
• Lagerbedingungen: protect from light; under inert gas
• Farbe: off-white
• mp (Schmelzpunkt): 127-128 °C (lit.)
• Löslichkeit: DMSO: >10 mg/mL
• Ersteller: GlaxoSmithKline
• Lagertemp.: 2-8°C
• SMILES String: CCCc1c(O)c(ccc1OCCCOc2ccc(OCC(O)=O)cc2)C(C)=O
• InChI: 1S/C22H26O7/c1-3-5-19-20(11-10-18(15(2)23)22(19)26)28-13-4-12-27-16-6-8-17(9-7-16)29-14-21(24)25/h6-11,26H,3-5,12-14H2,1-2H3,(H,24,25)
• InChIKey: HBBVCKCCQCQCTJ-UHFFFAOYSA-N
• Angaben zum Gen: human ... PPARD(5467)

Beschreibung

Anwendung

L-165,041 has been used as a peroxisome proliferator-activated receptor β/δ (PPARβ/δ) ligand to study its influence on PPARβ/δ mediated postnatal myogenesis in C2C12 myoblasts.

Biochem./physiol. Wirkung

L-165041 dose-dependently blocks rat vascular smooth muscle cell (VSMC) proliferation and migration by inducing the cell cycle arrest. It has the potential to treat pathological cardiovascular conditions, such as restenosis and atherosclerosis. L-165041 also effectively inhibits the progression of diabetic nephropathy. It exhibits anti-apoptosis and anti-angiogenic effects.

PPARβ (PPARδ) selective agonist.

Leistungsmerkmale und Vorteile

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable
• Persönliche Schutzausrüstung: Eyeshields, Gloves, type N95 (US)